Neuroptix eyes $18.5m for Alzheimer's test
This article was originally published in Clinica
Executive Summary
Acton, Massachusetts-based Neuroptix is to inject $18.5m it has raised in a series B financing round into the continued development of its non-invasive eye test for Alzheimer's disease. The Sapphire system works by using a non-contact optical device, combined with an eye drop to identify Alzheimer's-related proteins found in the lens of the eye. According to the company, results from preclinical testing have indicated that the amyloid-beta proteins, associated with the formation of brain plaques found in Alzheimer's patients, can be detected in the eye before they aggregate in the brain. Healthcare venture capitalist Inventages was the lead investor in the financing round.